These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 20610479)

  • 1. Cancer-testis antigen expression in triple-negative breast cancer.
    Curigliano G; Viale G; Ghioni M; Jungbluth AA; Bagnardi V; Spagnoli GC; Neville AM; Nolè F; Rotmensz N; Goldhirsch A
    Ann Oncol; 2011 Jan; 22(1):98-103. PubMed ID: 20610479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of tumor-associated antigens in breast cancer subtypes.
    Curigliano G; Bagnardi V; Ghioni M; Louahed J; Brichard V; Lehmann FF; Marra A; Trapani D; Criscitiello C; Viale G
    Breast; 2020 Feb; 49():202-209. PubMed ID: 31869767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of MAGE-A and NY-ESO-1 cancer/testis antigens is enriched in triple-negative invasive breast cancers.
    Raghavendra A; Kalita-de Croft P; Vargas AC; Smart CE; Simpson PT; Saunus JM; Lakhani SR
    Histopathology; 2018 Jul; 73(1):68-80. PubMed ID: 29465777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers.
    Chen YT; Ross DS; Chiu R; Zhou XK; Chen YY; Lee P; Hoda SA; Simpson AJ; Old LJ; Caballero O; Neville AM
    PLoS One; 2011 Mar; 6(3):e17876. PubMed ID: 21437249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer.
    Ademuyiwa FO; Bshara W; Attwood K; Morrison C; Edge SB; Karpf AR; James SA; Ambrosone CB; O'Connor TL; Levine EG; Miliotto A; Ritter E; Ritter G; Gnjatic S; Odunsi K
    PLoS One; 2012; 7(6):e38783. PubMed ID: 22761704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer.
    Badovinac Črnjević T; Spagnoli G; Juretić A; Jakić-Razumović J; Podolski P; Šarić N
    Med Oncol; 2012 Sep; 29(3):1586-91. PubMed ID: 22116775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?
    Tessari A; Pilla L; Silvia D; Duca M; Paolini B; Carcangiu ML; Mariani L; de Braud FG; Cresta S
    Breast; 2018 Dec; 42():68-73. PubMed ID: 30189381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CT-X antigen expression in human breast cancer.
    Grigoriadis A; Caballero OL; Hoek KS; da Silva L; Chen YT; Shin SJ; Jungbluth AA; Miller LD; Clouston D; Cebon J; Old LJ; Lakhani SR; Simpson AJ; Neville AM
    Proc Natl Acad Sci U S A; 2009 Aug; 106(32):13493-8. PubMed ID: 19651608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development.
    Gjerstorff MF; Kock K; Nielsen O; Ditzel HJ
    Hum Reprod; 2007 Apr; 22(4):953-60. PubMed ID: 17208940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer.
    Wang Y; Wu XJ; Zhao AL; Yuan YH; Chen YT; Jungbluth AA; Gnjatic S; Santiago D; Ritter G; Chen WF; Old LJ; Ji JF
    Cancer Immun; 2004 Nov; 4():11. PubMed ID: 15516106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.
    Cabezón T; Gromova I; Gromov P; Serizawa R; Timmermans Wielenga V; Kroman N; Celis JE; Moreira JM
    Mol Cell Proteomics; 2013 Feb; 12(2):381-94. PubMed ID: 23172894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: retrospective immunohistochemical study.
    Matković B; Juretić A; Spagnoli GC; Separović V; Gamulin M; Separović R; Sarić N; Basić-Koretić M; Novosel I; Kruslin B
    Croat Med J; 2011 Apr; 52(2):171-7. PubMed ID: 21495200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue.
    Li M; Yuan YH; Han Y; Liu YX; Yan L; Wang Y; Gu J
    Clin Cancer Res; 2005 Mar; 11(5):1809-14. PubMed ID: 15756003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer.
    Laban S; Atanackovic D; Luetkens T; Knecht R; Busch CJ; Freytag M; Spagnoli G; Ritter G; Hoffmann TK; Knuth A; Sauter G; Wilczak W; Blessmann M; Borgmann K; Muenscher A; Clauditz TS
    Int J Cancer; 2014 Sep; 135(5):1142-52. PubMed ID: 24482145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy.
    Hamaï A; Duperrier-Amouriaux K; Pignon P; Raimbaud I; Memeo L; Colarossi C; Canzonieri V; Perin T; Classe JM; Campone M; Jézéquel P; Campion L; Ayyoub M; Valmori D
    PLoS One; 2011; 6(6):e21129. PubMed ID: 21747904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease.
    Dhodapkar MV; Osman K; Teruya-Feldstein J; Filippa D; Hedvat CV; Iversen K; Kolb D; Geller MD; Hassoun H; Kewalramani T; Comenzo RL; Coplan K; Chen YT; Jungbluth AA
    Cancer Immun; 2003 Jul; 3():9. PubMed ID: 12875607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours.
    Ishihara M; Kageyama S; Miyahara Y; Ishikawa T; Ueda S; Soga N; Naota H; Mukai K; Harada N; Ikeda H; Shiku H
    BMC Cancer; 2020 Jun; 20(1):606. PubMed ID: 32600281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of MAGE-A3/6 in primary breast cancer is associated with hormone receptor negative status, high histologic grade, and poor survival.
    Ayyoub M; Scarlata CM; Hamaï A; Pignon P; Valmori D
    J Immunother; 2014; 37(2):73-6. PubMed ID: 24509169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms.
    Yakirevich E; Sabo E; Lavie O; Mazareb S; Spagnoli GC; Resnick MB
    Clin Cancer Res; 2003 Dec; 9(17):6453-60. PubMed ID: 14695148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.